Dr. Yeh is a professor in the Departments of Surgery and Pharmacology at the University of North Carolina (UNC) at Chapel Hill, Vice Chair of Research in the Department of Surgery, and co-Director of Clinical Research at the UNC Lineberger Comprehensive Cancer Center. She joined the faculty at UNC in 2005 and was recently named an Oliver Smithies Investigator (honoring the late Nobel Prize winner at UNC). She maintains an active clinical practice specializing in endocrine diseases (thyroid, parathyroid, adrenal) and pancreatic cancers. Her research focus centers on the use of genomics to identify new approaches for pancreatic cancer.
Dr. Yeh received her medical degree from Johns Hopkins University and completed her general surgery residency at the Boston Medical Center, a research fellowship at Dana-Farber Cancer Institute, and a surgical oncology fellowship at the Memorial-Sloan Kettering Cancer Center.
In 2015, Dr. Yeh identified new molecular subtypes of pancreatic cancer that have clinical and treatment significance. To translate molecular subtypes to the clinic, her group developed a single sample classifier that is now licensed to GeneCentric Therapeutics. Dr. Yeh and her collaborators also have developed a device that could help drive chemotherapy drugs directly into pancreatic tumor tissue to prevent their growth and shrink them. Dr. Yeh co-founded Advanced Chemotherapeutic Technologies, Inc. in order to bring the device into clinical trials.